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Abstract
Background: The topical application of methylnicotinate results in a localized vasodilatatory
response which has been found to differ from that observed to occur in healthy controls in a variety
of medical conditions. The stability of the drug in aqueous solution is unclear while difficulties can
be encountered when preparing methylnicotinate solutions for this purpose. To aid in the
determination of how long solutions of the drug should be stored before discarding we have used
a collection of aged batches of methylnicotinate to determine the stability of the drug in aqueous
solution.
Findings: The degradation of methylnicotinate was determined in batches which had been stored
at 4°C for between 5 and 1062 days prior to analysis by High Performance Liquid Chromatography.
The major degradation product of methylnicotinate was nicotinic acid which formed at an
approximate rate of 0.5% of the starting methylnicotinate concentration per annum. Furthermore,
the ability of methylnicotinate solutions of different ages to induce vasodilatation was assessed in
healthy volunteers. No significant difference in vasodilatatory response was apparent between
batches which had been stored for between zero and 1057 days.
Conclusion:  Methylnicotinate exhibits excellent chemical and biological stability in solution
facilitating its use in clinical applications.
Background
Systemic administration of the B vitamin niacin (nicotinic
acid) produces a generalized vasodilatatory response [1].
This occurs due to nicotinic acid stimulating the produc-
tion of prostaglandin D2 from arachidonic acid in the skin
which subsequently acts upon capillary endothelial cells
to cause vasodilatation [1,2]. The methylester of nicoti-
nate, methylnicotinate, has a similar vasodilatatory effect,
however the ester can be applied transcutaneously result-
ing in a localized, rather than generalized, response [3].
Methylnicotinate has found application as a rubefacient
[4] and in the development and testing of anti-inflamma-
tory drugs [5]. Topical application of methylnicotinate
has also been used to investigate the inflammatory
response in a variety of disorders including autism [6],
Huntington's disease [7], social phobia [8], major depres-
sive disorder [9,10] and schizophrenia [3,10-18]. In this
latter application varying doses of methynicotinate are
applied to the skin (normally the forearm) in the form of
a patch (frequently, if inaccurately, referred to as a 'niacin
patch'). The resulting vasodilatatory response is then
measured either by the visual estimation of erythema
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[4,9] or measuring superficial blood flow by laser Doppler
spectrometry [8,13,14]. Such studies have been compli-
cated by the fact that the stability of methylnicotinate in
aqueous solution is unknown, necessitating the prepara-
tion of new solutions on a regular basis. Besides introduc-
ing an additional source of error, the production of new
batches of the drug is made difficult due to the high degree
of hygroscopicity of solid methylnicotinate. This results in
storage and handling difficulties and an inevitable need to
regularly discard batches of the solid ester. It would there-
fore be beneficial to store the aqueous solution for
extended periods of time. The stability of methylnicoti-
nate in aqueous solution is not known however, and
hence it is unclear for how long the solutions can be
stored for. As such many batches of the aqueous drug have
been prepared and stored over several years. This has
allowed us to investigate the stability of methylnicotinate
in solution as well as testing the effect of storage time on
the ability of aged preparations to induce erythema, as an
aid to determining the storage life of the solution.
Analysis of methylnicotinate degradation in 
aqueous solution
Methylnicotinate (NHS Highland Labs, UK) was prepared
at a concentration of 1 M in water and stored at 4°C in
glass containers for between 5 – 1062 days prior to analy-
sis. All batches were prepared using an identical protocol
in the same laboratory. No differences in colour or clarity
were discernable by visual inspections between batches of
different ages, and no batches contained any visible pre-
cipitate. The chemical stability of methylnicotinate was
investigated using High Performance Liquid Chromatog-
raphy (HPLC). To accomplish this 1 M stock solutions of
methylnicotinate were diluted and methylnicotinate and
a degradation product, nicotinic acid, determined in
quadruplicate by HPLC using the following analysis
parameters: injection volume: 20 μL; separator column:
Supelco (Sigma, UK) supelcosil TM LC-18 ODS-18,
(length: 25 cm, internal diameter: 4.6 mm, particule size:
5 μm); eluant: 25% v/v methanol in water; eluant flow
rate: 1.5 mL/min. Eluted compounds were detected by UV
@ 263 nm using an Applied Biosystems Spectroflow 757
UV-vis detector and quantified by comparision with nico-
tinic acid and 6-methylnicotinate standards (Aldrich,
UK). Nicotinic acid had a retention time of 1.4 minutes
and a limit of detection of 0.04 μg/ml, while methylnico-
tinate exhibited a retention time of 7.3 minutes and a
limit of detection of 0.05 μg/ml. Within-day variance
expressed as the standard deviation as a percentage of the
mean was 0.8%, and between day variance was 1.5%. The
detection of both nicotinate and methylnicotinate
showed a linear response with respect to concentration
(Pearson correlation coefficient of detector response vs.
applied quantity was 0.98) over the range tested using
freshly prepared standards (maximum concentration
tested was 150 μg/ml).
The concentration of methylnicotinate in each batch did
not differ significantly between batches of different ages,
all having the expected measured concentration of
approximately 1 M (Figure 1), and there was no signifi-
cant linear relationship with batch age (Pearson correla-
tion coefficient was 0.001; P  > 0.05). Qualitative
assessment of the chromatograms of freshly prepared
methylnicotinate indicated that apart from the com-
pound itself, the predominant contaminant co-eluted
with nicotinic acid. Representative chromatograms are
shown in Figure 2. The concentration of nicotinic acid in
a batch of methylnicotinate prepared 5 days previously
was 0.060 ± 0.002% (mean ± SD nicotinate as a percent-
age of methylnicotinate analysed in quadruplicate). As
illustrated in Figure 1 the degradation of methylnicotinate
to form nicotinic acid proceeded linearly with respect to
time (Pearson correlation coefficient = 0.98) at a rate of
0.00150% per day (95% confidence interval was
0.001270% to 0.00172%) or 0.54% per 365 day year
(95% confidence interval was 0.47% to 0.63%).
Erythema response
In addition to the HPLC analysis, the vasodilatatory activ-
ity of aged solutions was also investigated. The four
batches utilised had been stored for 0, 320, 725 and 1057
days respectively at the time of testing. The 1 M stock solu-
tions were diluted to 10 mM and 1 cm2 paper patches were
impregnated with approximately 30 μl of the solution as
previously described in detail [4]. The patches were
applied to the forearms of eight healthy volunteers (4
male, 4 female, age was 44 ± 12 years [mean ± SD]. The
area of skin to which the patch was applied was examined
for, and was free of, damage. The skin patch procedure
had been reviewed and approved by NHS Highlands
Research Ethics Committee. All subjects gave informed
consent including that the data obtained from their partic-
ipation may be published in aggregate format. Erythema,
monitored at 5, 10 and 15 minutes after application, was
assessed visually using a 4 point scale (0 – no erythema, 1
– perceptible but slight erythema, 2 – moderate erythema,
3 – pronounced erythema). As illustrated in Figure 3, the
batch age had no effect upon the extent of erythema (2-
way ANOVA with factors time and batch age). There was
no statistically significant interaction between time and
batch age (F6,56 = 0.21; P > 0.9) nor was their a significant
effect of batch age (F3,56 = 0.16; P > 0.9), although there
was a statistically significant effect of time (F2,56 = 175.34;
P < 0.0001)). The testing of the ability of each batch of
methylnicotinate to induce erythema was performed
using a single dose. We cannot rule out that an effect of
batch age would have been observed using different, espe-
cially lower, concentrations, although we consider such aBMC Research Notes 2008, 1:89 http://www.biomedcentral.com/1756-0500/1/89
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possibility unlikely. It has been reported that methylnico-
tinate-induced erythema is reduced with age [19]. We did
not observe, however, a statistically significant correlation
between age and erythema (for example the Pearson cor-
relation coefficient between erythema at 15 minutes and
subject age was – 0.31; P < 0.05), although the small sam-
ple size may have prevented us from detecting such a rela-
tionship.
Conclusion
Our data suggests that the degradation of methylnicoti-
nate proceeds slowly in aqueous solution. Chromato-
graphic analysis indicates that the methylester gradually
hydrolyses at the rate of approximately 0.5% per annum
to form nicotinic acid and, presumably, methanol. No
other degradation products were noted. This rate of degra-
dation had no apparent effect upon the ability of aged
batches, prepared up to approximately 3 years prior, to
induce erythema in healthy subjects. Since erythema was
determined visually it remains a possibility that detection
methods which are able to detect smaller changes in
blood flow, such as laser Doppler spectroscopy, would
have detected an effect of storage time. Such a possibility
is unlikely, however, given that the extent of degradation
in batches prepared 1062 days prior (approximately
1.5%) is rather lower than the test-retest variance of laser
Doppler measurements which are in the range of 5 – 10%
(BMR, unpublished observations). It is important to note
that the methylnicotinate solutions used in this study had
a concentration of 1 M and had been stored refrigerated at
4°C in glass containers. It is possible that storage of solu-
tions at different concentrations, or in containers made
from substances other than glass would have given con-
trary results due to, for example, absorption to the surface
of the container. Moreover, storage at higher temperatures
e.g. room temperature would likely have resulted in
higher rates of degradation, although it is common for test
reagents to be stored in a refrigerator. Nevertheless, our
overall conclusion is that methylnicotinate solutions can
be stored for extended periods of time at 4°C in glass con-
tainers without the occurrence of extensive chemical deg-
radation or loss of biological activity. This finding may aid
the use of methylnicotinate for research purposes or for
future clinical diagnostic uses.
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Relationship between batch age, methylnicotinate concentration and relative nicotinic acid content of 1 M aqueous solutions of  methylnicotinate Figure 1
Relationship between batch age, methylnicotinate concentration and relative nicotinic acid content of 1 M 
aqueous solutions of methylnicotinate. Batches of 1 M methylnicotinate were stored at 4°C for increasing lengths of time 
prior to analysis by HPLC. Filled circles, plotted on the right axis, show the measured concentration of methylnicotinate in 
each batch. Open circles, plotted on the left axis, show the percentage of nicotinic acid relative to the total methylnicotinate 
plus nicotinic acid concentration in each batch. Values shown are the mean of quadruplicate determinations; bars indicate the 
standard deviation. The 'best-fit' linear regression line for the correlation between batch age and nicotinic acid content is indi-
cated by a solid line; the dotted lines indicate the 95% confidence intervals for this line based on the available data.BMC Research Notes 2008, 1:89 http://www.biomedcentral.com/1756-0500/1/89
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